Abbott
Abbott (NYSE:ABT) received FDA emergency use authorization for its virtually-guided, at-home BinaxNow COVID-19 Ag card on Dec. 16.
The test is a telehealth-supported prescription test that can be performed from home. It costs $25 and is similar in design to some pregnancy tests as it produces results within minutes through an accompanying app without having to send samples to a lab.
Abbott partnered with eMed on the home antigen test.